Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences Inc (NQ: ENSC )

0.1778 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ensysce Biosciences Inc

< Previous 1 2 3 4 Next >
Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR
Via ACCESSWIRE
Ensysce Biosciences Issues 2024 Shareholder Letter
Via ACCESSWIRE
Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023
Via ACCESSWIRE
Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic
Via ACCESSWIRE
Ensysce Biosciences Discusses TAAP and MPAR(R) Applications and OncoZenge Partnership with The Stock Day Podcast
Via ACCESSWIRE
Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing
Via ACCESSWIRE
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United States
Via ACCESSWIRE
Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study
Via ACCESSWIRE
Ensysce Biosciences Reports Third Quarter 2023 Financial Results
Via ACCESSWIRE
Ensysce Biosciences Secures $1.7 Million Convertible Note Financing
Via ACCESSWIRE
Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360
Via ACCESSWIRE
Ensysce Biosciences Releases "Highlights Video" of PAINWeek 2023 Symposium
Via ACCESSWIRE
Ensysce Biosciences to Chair the Fierce New Product Planning Summit 2023
Via ACCESSWIRE
Ensysce Biosciences Announces Completion of Site Initiation Visit for PF614-201 Clinical Study
Via ACCESSWIRE
Ensysce Biosciences to Host Research and Development FAQ Session Following PAINWeek Symposium on September 21, 2023
Via ACCESSWIRE
Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies
Via ACCESSWIRE
Ensysce Presents "A New Generation of Safer Pain Treatments"
Via ACCESSWIRE
Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Via ACCESSWIRE
Ensysce Biosciences to Present Clinical Dataset at Major PAINWeek Scientific Symposium
Via ACCESSWIRE
Ensysce Biosciences Reports Second Quarter 2023 Financial Results
Via ACCESSWIRE
Ensysce Biosciences Announces IRB Approval of Key Study Protocol
Via ACCESSWIRE
Ensysce Biosciences Announces Engagement of Alacrita Consulting
Via ACCESSWIRE
Ensysce Biosciences and Quotient Sciences to Present MPAR(R) Overdose Protection Platform at Upcoming CRS 2023 Annual Meeting and Expo
Via ACCESSWIRE
Ensysce Biosciences Regains Compliance with Nasdaq
Via ACCESSWIRE
Ensysce Biosciences Releases Updated Investor Presentation Available Via Investor Relations Website
Via ACCESSWIRE
Ensysce Biosciences to Participate in Upcoming Industry Events
Via ACCESSWIRE
Ensysce Biosciences Reports First Quarter 2023 Financial Results
Via ACCESSWIRE
Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering
Via ACCESSWIRE
Ensysce Biosciences, Inc. Announces Pricing of $7 Million Public Offering
Via ACCESSWIRE
Ensysce Biosciences (NASDAQ: ENSC) Successfully Completes Overdose-Protection Study
Ensysce Biosciences, Inc. (NASDAQ: ENSC) operates as a clinical-stage biotechnology company, which is focused on leveraging its proprietary technology to 
Via Spotlight Growth
Exposures Product Safety
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.